Diretrizes brasileiras para o manejo da agitação psicomotora: tranquilização rápida 2 – combinações e grupos especiais
DOI:
https://doi.org/10.25118/2763-9037.2021.v11.14Palabras clave:
Agitação psicomotora, agressividade, agentes tranquilizantes, emergência, transtornos mentaisResumen
Neste último artigo, faremos a comparação entre os diferentes grupos medicamentosos. Posteriormente, apresentaremos as possíveis combinações de medicações para a tranquilização rápida. Por fim, abordaremos o manejo de grupos especiais em agitação psicomotora.
Descargas
Métricas
Citas
International Society of Substance use Professionals (ISSUP). Saúde mental e considerações psicossociais durante o surto de COVID-19 [Internet]. 2020 Apr 3 [cited 2020 Dec 8]. www.issup.net/pt-br/knowledgeshare/publications/2020-04/saude-mentalconsideracoes-psicossociais-durante-surto-covid
Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46:752-7.
Morgan VA, Waterreus A, Carr V, Castle D, Cohen M, Harvey C, et al. Responding to challenges for people with psychotic illness: updated evidence from the survey of high impact psychosis. Aust N Z J Psychiatry 2017;51:124-40.
Saxena S, Major M. Physical health of people with severe mental disorders: leave no one behind. World Psychiatry. 2017;16:1-2. 5.Saraceno B, Levav I, Kohn R. The public mental health significance of research on socio-economic factors in schizophrenia and major depression. World Psychiatry. 2005;4:181-5.
Green MF, Horan WP, Lee J, McCleery A, Reddy LF, Wynn JK. Social disconnection in schizophrenia and the general community. Schizophr Bull. 2018;44:242-9.
Thornicroft G, Brohan E, Rose D, Norman Sartorius, Morven Leese, INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional surveyl. Lancet. 2009;373:408-15.
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611-27.
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22.
British Geriatrics Society. Coronavirus: Managing delirium in confirmed and suspected cases [Internet]. 2020 Mar 19 [cited 2020 Dec 7]. www.bgs.org.uk/resources/coronavirus-managingdelirium-in-confirmed-and-suspected-cases
Cui LB, Wang XH, Wang HN. Challenges of facing coronavirus disease 2019: Psychiatric services for patients with mental disorders. Psychiatry Clin Neurosci. 2020;74:371-2.
Baldacara L, Ismael F, Leite V, Pereira LA, Dos Santos RM, Gomes Júnior VP, et al. Brazilian guidelines for the management of psychomotor agitation. Part 1. Non-pharmacological approach. Braz J Psychiatry. 2019;41:153-67.
Organização Pan-Americana da Saúde (OPAS). Prevenção e controle de infecções durante os cuidados de saúde quando suspeita-se de infecção por novo coronavírus (nCoV) [Internet]. 2020 Mar 3 [cited 2020 Dec 8]. iris.paho.org/handle/10665.2/51910
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683-90.
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268-70.
O’Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49:497-8.
Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vázquez G, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86-128.
World Health Organization. Mental health and psychosocial considerations during the COVID-19 outbreak. Geneva: WHO; 2020.
Richmond JS, Berlin JS, Fishkind AB, Holloman GH Jr, Zeller SL, Wilson MP, et al. Verbal De-escalationof the agitated patient: consensus statement of the American Association for emergency psychiatry project BETA De-escalation workgroup. West J Emerg Med. 2012;13:17-25.
Baldacara L, Diaz AP, Leite V, Pereira LA, Dos Santos RM, Gomes Júnior VP, et al. Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach. Braz J Psychiatry. 2019;41:324-35.
Shulman M, Njoku IJ, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013;104:175-84.
Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142:184-6.
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995-2002.
Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148-50.
Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213-21.
Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, et al. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, doubleblind, parallel-group trial. Int Clin Psychopharmacol. 2015;30:142-50.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Debates em Psiquiatria permite que el (los) autor (es) mantenga(n) sus derechos de autor sin restricciones. Permite al (los) autor (es) conservar sus derechos de publicación sin restricciones. Los autores deben garantizar que el artículo es un trabajo original sin fabricación, fraude o plagio; no infringe ningún derecho de autor o derecho de propiedad de terceros. Los autores también deben garantizar que cada uno atendió a los requisitos de autoría conforme a la recomendación del ICMJE y entienden que, si el artículo o parte de él es fallido o fraudulento, cada autor comparte la responsabilidad.
Reconocimiento-NoComercial 4.0 internacional (CC BY-NC 4.0) - Debates em Psiquiatria es regida por la licencia CC-BY-NC
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia. Bajo las condiciones siguientes:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
























